CVS CVS HEALTH Corp

NYSE Retail-Drug Stores and Proprietary Stores DE CIK: 0000064803
AI RATING
SELL
72% Confidence

Investment Thesis

CVS demonstrates concerning fundamental deterioration with revenue growth of 7.8% failing to translate into earnings expansion (net income flat YoY) and EPS declining sharply 62%, indicating severe margin compression and/or shareholder dilution. Weak liquidity metrics (current ratio 0.87x, quick ratio 0.66x) combined with poor capital efficiency (ROE 3.8%, ROA 1.2%) and high debt burden ($60.5B) relative to profitability suggest the business is struggling to create shareholder value despite scale.

Strengths

  • + Positive revenue growth of 7.8% YoY demonstrates continued market demand
  • + Positive free cash flow generation of $3.4B provides debt servicing capacity
  • + Adequate interest coverage ratio of 6.5x indicates debt is manageable at current levels

Risks

  • ! Severe margin compression: 7.8% revenue growth producing 0.0% net income growth signals deteriorating profitability
  • ! Alarming liquidity position with current ratio 0.87x and quick ratio 0.66x indicating potential short-term payment challenges
  • ! Historically poor capital returns (ROE 3.8%, ROA 1.2%) and 62% EPS decline suggest structural business challenges and significant shareholder dilution
  • ! High leverage with $60.5B long-term debt limits financial flexibility despite manageable 0.78x debt-to-equity ratio

Key Metrics to Watch

Financial Metrics

Revenue
100.4B
Net Income
2.9B
EPS (Diluted)
$2.30
Free Cash Flow
3.4B
Total Assets
253.0B
Cash
9.5B

Profitability Ratios

Gross Margin 21.3%
Operating Margin 4.7%
Net Margin 2.9%
ROE 3.8%
ROA 1.2%
FCF Margin 3.4%

Balance Sheet & Liquidity

Current Ratio
0.87x
Quick Ratio
0.66x
Debt/Equity
0.78x
Debt/Assets
69.3%
Interest Coverage
6.54x
Long-term Debt
60.5B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-08T09:49:54.643382 | Data as of: 2026-03-31 | Powered by Claude AI